Clinical trials: Adjuvant Drug Therapy
Chemotherapy-induced Peripheral Neuropathy
A Study to Investigate the Safety and Efficacy of TRK-750 for the Treatment of Patients With CIPN (Chopin Study)
The primary objective of the study is: to assess the safety and tolerability of multiple oral (twice daily [BID]) doses of TRK-750 in oxaliplatin-treated colorectal cancer patients with chemotherapy-induced peripheral neuropathy…
- Trial name
- NCT04282590
- Sponsor
- Toray Industries, Inc
Breast Cancer Females, Triple Negative Breast Cancer (TNBC)
Adjuvant Intensification for LAR
This study enrolled patients with early-stage triple-negative breast cancer who had undergone radical surgery. The postoperative pathology met the TNM staging criteria of pT1c-3N0-3M0, and immunohistochemistry (IHC) results…
- Trial name
- POLARIS (NCT07407517)
- Testing
- Everolimus 10 mg daily
- Volunteers
- 904 people
- Sponsor
- Fudan University
Lung Cancer
Adjuvant Gemcitabine Plus Oxaliplatin Versus Gemcitabine Plus Cisplatin for Completely Resected Stage IB/II/IIIA NSCLC
Oxaliplatin has a more manageable toxicity profile than cisplatin, with no renal toxicity and a lower incidence of hematological and gastrointestinal toxicities.
- Trial name
- NCT00452881
- Testing
- gemcitabine, Oxaliplatin, Cisplatin
- Where
- South Korea
- Volunteers
- 151 people
- Sponsor
- National Cancer Center, Korea
Gastric Cancer
S-1-induced Lacrimal Drainage Obstruction
S-1 is an effective drug in gastric cancer (GC) for palliative chemotherapy in Eastern and Western patients. Recently, S-1 has been also reported to be an effective adjuvant therapy for GC patients who received D2 surgery in…
- Trial name
- NCT01486472
- Testing
- S-1
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Seoul National University Bundang Hospital
Triple Negative Breast Cancer
A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer
This is a 3 arm Phase 3 study to evaluate the safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy in…
- Trial name
- NCT02032277
- Testing
- Cyclophosphamide, Doxorubicin, Paclitaxel
- Where
- 158 sites in United States, Australia and 13 more
- Volunteers
- 634 people
- Sponsor
- AbbVie
Gastric Cancer
SOX as Adjuvant Chemotherapy for Resectable Gastric Cancer
The purpose of this study is to assess the safety and efficacy of S-1 plus oxaliplatin combination chemotherapy based on the adverse events and survival period by performing a phase I/II study of this combination in patients with…
- Trial name
- NCT01542294
- Testing
- s1, Oxaliplatin
- Where
- China
- Volunteers
- 71 people
- Sponsor
- Chinese Academy of Medical Sciences
Colorectal Cancer Metastatic
Chemotherapy Alone Versus Chemotherapy Plus Targeted Therapy as Adjuvant Therapy for Initially Unresectable Colorectal Cancer Liver Metastases
Chemotharapy plus targeted therapy regimen, as an adjuvant therapy, can effectively reduce the rate of both intrahepatic and extrahepatic recurrence in initially unresectable CRLM patients.
- Trial name
- NCT06027775
- Testing
- Targeted agent
- Volunteers
- 198 people
- Sponsor
- Fudan University
Breast Cancer
Study of Vitamin D Supplementation Tailored to Vitamin D Deficiency in Breast Cancer Patients
The purpose of this study is to compare normalization of vitamin D serum level after 6 months of vitamin D supplementation adjusted to baseline vitamin D serum level vs.conventional vitamin D supplementation.
- Trial name
- VITACAL (NCT01480869)
- Testing
- calcium and cholecalciferol
- Where
- France
- Volunteers
- 215 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Osteosarcoma
Adjuvant High-Dose Thiotepa and Stem Cell Rescue Associated With Conventional Chemotherapy in Relapsed Osteosarcoma
Approximately 150 new cases of osteosarcoma are reported each year in France, of which 15 to 20% are metastatic. Further to the initial standard care, about 45% of the patients relapse within a median duration of 20 months.
- Trial name
- OSII-TTP (NCT00978471)
- Testing
- Thiotepa
- Where
- 23 sites in France
- Volunteers
- 44 people
- Sponsor
- Centre Leon Berard
Distal Cholangiocarcinoma, Adjuvant Chemotherapy
Role of Adjuvant Chemotherapy in Distal Cholangiocarcinoma
Recent studies addressing the role of adjuvant chemotherapy in cholangiocarcinoma (CCA) have been published; however, there are challenges in generalizing the findings due to different prognostic characteristics depending on…
- Trial name
- NCT06671431
- Testing
- Adjuvant chemotherapy
- Volunteers
- 578 people
- Sponsor
- Seoul National University Hospital
Breast Neoplasm Malignant Primary, Lymphedema Arm
Agentic AI App and Home Bioimpedance Monitoring for Endocrine Therapy Adherence and Lymphedema in Breast Cancer Survivors
As survival rates following breast cancer surgery continue to improve, long-term survivorship management has emerged as a crucial clinical priority.
- Conditions
- Breast Neoplasm Malignant Primary, Lymphedema Arm, Medication Adherence, Ductal Carcinoma In Situ
- Trial name
- Pinkmate (NCT07911839)
- Testing
- Cohort1: Pinkmate Agentic AI-ePRO Active Management Platform, Cohort1: Pinkmate Basic Medication Reminders and Standard Outpatient Care, Cohort2: InBody BWA ON Home Bioimpedance Monitoring and Behavioral App
- Where
- South Korea
- Volunteers
- 264 people
- Sponsor
- Chang-Ik Yoon
Breast Cancer
Clodronate With or Without Chemotherapy and/or Hormonal Therapy in Treating Women With Stage I or Stage II Breast Cancer
RATIONALE: Clodronate may be effective in preventing the spread of cancer to the bones and other parts of the body. It is not yet known whether clodronate is more effective alone or combined with chemotherapy and /or hormonal…
- Trial name
- NCT00009945
- Testing
- clodronate
- Where
- 17 sites in United States
- Volunteers
- 3,323 people
- Sponsor
- NSABP Foundation Inc
Ovarian Cancer
Circulating Tumour DNA as a Marker of Residual Disease & Response to Adjuvant Chemotherapy in Stage I-IV Ovarian Cancer
To demonstrate that detectable ctDNA in peripheral blood following debulking of the primary tumour or following completion of adjuvant treatment for is associated with subsequent disease recurrence in stage I-IV epithelial…
- Trial name
- NCT03691012
- Testing
- Circulating tumour DNA testing
- Where
- 7 sites in United States, Australia
- Volunteers
- 118 people
- Sponsor
- Walter and Eliza Hall Institute of Medical Research
CIPN in Adjuvant Breast Cancer Patients
Prevention of CIPN Using Compressive Therapy
Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of treatment with taxanes and platinum-based drugs, significantly impacting the quality of life of oncology patients.
- Trial name
- CIPN (NCT06823440)
- Testing
- Compression using surgical gloves and compression knee socks
- Where
- Czechia
- Volunteers
- 100 people
- Sponsor
- Martina Lojova
Carcinoma, Non-Small-Cell Lung
TAilored Post-Surgical Therapy in Early Stage NSCLC
Our hypothesis is that patients receiving therapy based on their baseline tumor ERCC1 levels and EGFR mutations would attain better disease free survival rates than patients in the control arm receiving noncustomized therapy.
- Trial name
- TASTE (NCT00775385)
- Testing
- Standard Chemotherapy, Customized Treatment
- Where
- 42 sites in France
- Volunteers
- 152 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Gastric Cancer, HER2-positive Gastric Cancer
Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease
TRINITY is designed as a multicentre, randomized, open-label, interventional phase II study aimed at investigating the activity, efficacy and safety of trastuzumab-deruxtecan (T-DXd) plus capecitabine/5-fluorouracil as a…
- Trial name
- TRINITY (NCT06253650)
- Testing
- Experimental, Control
- Where
- Italy
- Volunteers
- 46 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Bladder Cancer
Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, cisplatin, and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00777491
- Testing
- induction cisplatin, induction 5-fluorouracil, induction gemcitabine
- Where
- 11 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- Radiation Therapy Oncology Group
Esophageal Cancer
Irinotecan, Cisplatin, and Radiation Therapy With or Without Celecoxib in Treating Patients With Stage II, Stage III, or Stage IV Esophageal Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00520091
- Testing
- CPT- 11, Cisplatin, Celecoxib
- Volunteers
- 14 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Non-small Cell Lung Cancer
Huaier Granule for Prevention of Recurrence and Metastasis of Stage II and III Non-small Cell Lung Cancer (NSCLC)
This study including two parts，one part is a randomized clinical trial design，another part is a registration study.
- Trial name
- NCT03198117
- Testing
- Huaier Granule
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Qidong Gaitianli Medicines Co., Ltd
Stomach Cancer
S-1/Oxaliplatin for High Risk Patients Who Underwent Gastrectomy
After curative resection, patients with stage IIIB-IV (M0) gastric cancer were given chemotherapy as follows: S-1 orally at 80 mg/m2 divided in two daily doses for 14 days and oxaliplatin at 130 mg/m2 intravenously over 2 h every…
- Trial name
- SOHUG (NCT02191566)
- Testing
- S-1 (452500ACH), OXALIPLATIN (205803BIJ)
- Where
- South Korea
- Volunteers
- 8 people
- Sponsor
- Kangbuk Samsung Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.